CVS to pay $315 million to settle DOJ case alleging illegal opioid prescriptions

What This is

• CVS Pharmacy and several subsidiaries agreed to pay $315 million to settle Justice Department claims tied to opioid and other controlled-substance prescriptions.
• Federal prosecutors alleged CVS unlawfully dispensed medically unnecessary prescriptions for highly addictive opioids.
• The settlement resolves a 2024 federal complaint and also closes out a 2019 whistleblower lawsuit referenced by the Justice Department.
• CVS said it admits no wrongdoing and disputes the government’s allegations.
• The agreement requires CVS to add safeguards for dispensing controlled substances, including more proactive monitoring of opioid prescribing patterns.
• The settlement is part of broader federal efforts to hold pharmacies and other companies accountable for their role in the U.S. opioid crisis.

Why This Matters

• The case stresses how much responsibility pharmacies should take for catching suspicious controlled-substance prescriptions before they are filled.
• It puts CVS’s promised safeguards under scrutiny as a practical way to reduce misuse while still serving patients with legitimate pain needs.
• It raises the question of whether big settlements change corporate behavior or become a predictable cost of doing business.